Europe
Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.
Qiagen’s investment will be an expansion of its current operations in that northern England city.
The move is in part related to Brexit, the UK’s exit from the European Union.
News of the layoffs comes hard on the heels of the company’s credit rating having been cut to junk status by Fitch Rating.
Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.
Award of approximately USD 37 million will support clinical work required for product approval.
The price of a single pill went up from 16p to 9.22 pounds, even though production costs remained broadly stable during that period, the CMA said.
Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents.
HIV patients have a new maintenance drug in their arsenal of medication.
A look at the 19 spine-related medical devices the FDA cleared in October.
PRESS RELEASES